This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sakko, A. J. Articles by Horsfall, D. J. Search for Related Content PubMed Articles by Sakko, A. J. Articles by Horsfall, D. J.

Versican Accumulation in Human Prostatic Fibroblast Cultures Is Enhanced by Prostate Cancer Cell-derived Transforming Growth Factor ß1¹

Flinders Cancer Centre, Department of Surgery, Flinders University School of Medicine and Flinders Medical Centre, Adelaide, South Australia 5042, Australia [A. J. S., C. R., K. M., W. D. T., D. J. H.], and Division of Life Sciences, Cell and Molecular Biology, University of Texas at San Antonio, San Antonio, Texas 78249 [R. G. L.].

We have previously demonstrated that peritumoral stromal matrix derived from prostate cancer patients who relapse after radical surgery contains elevated levels of versican. The purpose of this study was to determine whether prostate cancer cells control stromal cell secretion of versican. Serum-free conditioned medium from three prostate adenocarcinoma cell lines, LNCaP, PC3, and DU145, was added to cultures of fibroblasts established from prostatic tissue of patients with benign prostatic hyperplasia, and the medium was harvested at 24, 48, and 72 h. Immunoblotting with an antiversican core protein antibody revealed that prostatic fibroblast medium harvested at 72 h contained increased levels of versican after treatment with either LNCaP-, PC3- or DU145-conditioned medium (2.5-, 4.5-, and 5-fold, respectively) compared with control cultures. This increase in versican in the culture medium was not observed after coincubation with transforming growth factor ß1-neutralizing antisera. The results of this study suggest that prostate tumor cells induce host stromal cells to secrete increased versican levels via a paracrine mechanism mediated by transforming growth factor ß1.

This article has been cited by other articles:

				E. M. Kozma, K. Olczyk, G. Wisowski, A. Glowacki, and R. Bobinski Alterations in the Extracellular Matrix Proteoglycan Profile in Dupuytren's Contracture Affect the Palmar Fascia J. Biochem., April 1, 2005; 137(4): 463 - 476. [Abstract] [Full Text] [PDF]

				D. L. Russell, S. A. Ochsner, M. Hsieh, S. Mulders, and J. S. Richards Hormone-Regulated Expression and Localization of Versican in the Rodent Ovary Endocrinology, March 1, 2003; 144(3): 1020 - 1031. [Abstract] [Full Text] [PDF]

				J. A. Tuxhorn, G. E. Ayala, M. J. Smith, V. C. Smith, T. D. Dang, and D. R. Rowley Reactive Stroma in Human Prostate Cancer: Induction of Myofibroblast Phenotype and Extracellular Matrix Remodeling Clin. Cancer Res., September 1, 2002; 8(9): 2912 - 2923. [Abstract] [Full Text] [PDF]

				C. Ricciardelli, J. H. Brooks, S. Suwiwat, A. J. Sakko, K. Mayne, W. A. Raymond, R. Seshadri, R. G. LeBaron, and D. J. Horsfall Regulation of Stromal Versican Expression by Breast Cancer Cells and Importance to Relapse-free Survival in Patients with Node-negative Primary Breast Cancer Clin. Cancer Res., April 1, 2002; 8(4): 1054 - 1060. [Abstract] [Full Text] [PDF]

				M. Touab, J. Villena, C. Barranco, M. Arumi-Uria, and A. Bassols Versican Is Differentially Expressed in Human Melanoma and May Play a Role in Tumor Development Am. J. Pathol., February 1, 2002; 160(2): 549 - 557. [Abstract] [Full Text] [PDF]